Evidence map›Paper›PMID 26873905›Full record

Trial reportDiabetes & vascular disease research2016

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

Ian J Neeland, Darren K McGuire, Robert Chilton, Susanne Crowe, Søren S Lund, Hans J Woerle, Uli C Broedl, Odd Erik Johansen

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes & vascular disease research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 4 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 4 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Ian J NeelandDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA ian.neeland@utsouthwestern.edu.
Darren K McGuireDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Robert ChiltonUniversity of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Susanne CroweBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Søren S LundBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Hans J WoerleBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Uli C BroedlBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Odd Erik JohansenBoehringer Ingelheim Norway KS, Asker, Norway.
Boehringer Ingelheim (Germany) · DEThe University of Texas Southwestern Medical Center · USBoehringer Ingelheim (Norway) · NOThe University of Texas Health Science Center at San Antonio · US

Funding

Visceral Adiposity and Diabetes: Translating Form to Function Using ImagingK23DK106520 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI NEELAND, IAN JASON · 2015 to 2019
$776k
NIDDK NIH HHS 1K23DK106520-01NIDDK NIH HHS K23 DK106520
6 · The paper itself

Abstract

aimsTo determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus.

methodsChanges in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration.

resultsThis study comprised 3300 patients (cohort 1, N = 823; cohort 2, N = 2477). Empagliflozin reduced weight, waist circumference and adiposity indices versus placebo in both cohorts. Adjusted mean (95% confidence interval) change from baseline in empagliflozin versus placebo was -1.7 kg (-2.1 to -1.4 kg) and -1.9 kg (-2.1 to -1.7 kg) for body weight (p < 0.001); -1.3 cm (-1.8 to -0.7 cm) and -1.3 cm (-1.7 to -1.0 cm) for waist circumference (p < 0.001); -0.2% (-0.7% to 0.3%; p = 0.45) and -0.3% (-0.7% to 0.0%; p = 0.08) for estimated total body fat; -0.007 (-0.011 to -0.004) and -0.008 (-0.010 to -0.006) for index of central obesity (p < 0.001); and -0.3 (-0.5 to 0.0; p = 0.07) and -0.4 (-0.7 to -0.1; p = 0.003) for visceral adiposity index in cohorts 1 and 2, respectively. Adipose reductions were seen across most age, sex and waist circumference subgroups.

conclusionEmpagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.

Indexed as

AdiposityAdultAgedBenzhydryl CompoundsBlood GlucoseBody Mass IndexDiabetes Mellitus, Type 2FemaleGlucosidesHumansHypoglycemic AgentsMaleMetforminMiddle AgedObesityWeight LossBenzhydryl CompoundsBlood GlucoseempagliflozinGlucosidesHypoglycemic AgentsMetforminbody fat distributionempagliflozinObesitysodium glucose co-transporter 2 inhibitorvisceral adipose tissue

Identifiers

PMID26873905
PMCPMC4768401
OpenAlexW2294512307

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.